Why the study?
The study was conducted to compare people with Type 2 diabetes mellitus with and without heart failure regarding metabolic control, therapeutic regimens, and comorbidities.
In a large real-world registry, patients with Type 2 diabetes and heart failure demonstrated better metabolic and blood pressure control than those without heart failure, likely reflecting more intensive medical management.
Aim Comparing people with Type 2 diabetes mellitus with and without heart failure in terms of metabolic control, therapeutic regimen and comorbidities. Methods The Prospective Diabetes Registry ( DPV ) is a longitudinal documentation system for demographics, medical care and outcome in people with diabetes mellitus. It consists of follow‐up data from people with diabetes mellitus who have agreed to be recorded in the registry. Clinical data are submitted by general practitioners, specialists and clinics throughout Germany and Austria. Some 289 954 people with Type 2 diabetes mellitus (years 2000 to 2015) were analysed using demographic statistics and adjustment for confounders based on linear and logistic regression analysis. Results People with Type 2 diabetes mellitus ( ICD code: E11) and heart failure ( ICD code: I50) ( N = 14 723) were older, more often women and presented with longer diabetes duration compared with those without heart failure. After adjustment for age, gender and diabetes duration, people with heart failure showed lower HbA 1c , higher BMI and more intense insulin therapy. Analysis revealed that people with heart failure were more often treated with insulin, and more frequently received anti‐hypertensives and lipid‐lowering medication. They presented with lower systolic and diastolic BP . People with heart failure more frequently showed a history of comorbidities. Conclusion Heart failure is common in diabetes mellitus, but the prevalence in the DPV is lower frequent than expected. The reason for improved metabolic control in heart failure may be intensified therapy with insulin, lipid‐lowering medication and anti‐hypertensives in this cohort.
No takes yet. Share an insight, caveat, or question.
Stoyanova et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: